Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

PD-1

This page shows the latest PD-1 news and features for those working in and with pharma, biotech and healthcare.

AZ’s immuno-oncology combo fails another lung cancer trial

AZ’s immuno-oncology combo fails another lung cancer trial

Looking for the silver lining, AZ it was encouraged by the performance of PD-L1 inhibitor Imfinzi (durvalumab) as a monotherapy in a subgroup of patients in the trial, saying it ... The news is particularly disappointing given that Bristol-Myers

Latest news

  • Merck’s Keytruda meets survival challenge in NSCLC Merck’s Keytruda meets survival challenge in NSCLC

    Merck &Co’s grip on the first-line non-small cell lung cancer (NSCLC) immunotherapy market seems set to tighten, after its PD-1 inhibitor Keytruda halved the risk of death ... It’s another win for Merck in this treatment space over rival

  • BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

    The US regulator has given the green light to PD-1 inhibitor Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab) as an initial treatment for advanced renal cell carcinoma (RCC) patients on ... Roche has also reported Sutent-topping results with

  • Merck’s Keytruda scores in frontline lung cancer yet again Merck’s Keytruda scores in frontline lung cancer yet again

    In January, the drug become the drug in the PD-1/PD-L1 class to improve overall survival when given in combination with chemotherapy in previously-untreated patients in the ... are both hoping to find a role for combinations pairing PD-1/PD-L1 inhibitors

  • Incyte/Merck trial failure bodes ill for IDO class Incyte/Merck trial failure bodes ill for IDO class

    BMS is also partnered with Incyte on a trial of its PD-1 inhibitor Opdivo (nivolumab) with epacadostat, as is AstraZeneca with its PD-L1 blocker Imfinzi (durvalumab), so the blow ... That means for now, PD1/PD-L1 inhibitors as monotherapy, or combined

  • Sanofi’s PD-1 inhibitor starts EU review for skin cancer Sanofi’s PD-1 inhibitor starts EU review for skin cancer

    The EMA has kicked off its review of Sanofi and Regeneron’s immuno-oncology drug cemiplimab, which is aiming to become the sixth drug in the PD-1/PD-L1 inhibitor ... As of yet, none of the other PD-1/PD-L1-targeting drugs are approved for CSCC.

More from news
Approximately 21 fully matching, plus 199 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Option, collaboration. 1, 063. Syros Pharmaceuticals/ Incyte. Gene control platform to identify up to seven therapeutic targets with a focus in myeloproliferative neoplasms. ... used to progress the clinical development of the company's immuno-oncology

  • The good, the bad and the ugly The good, the bad and the ugly

    But that doesn’t tell the whole story. Pfizer comfortably remains the world’s largest pharma company (by global Rx sales), with an estimated 12.1% growth in 2017, lifting its ... Companies are looking to pair their PD-1/PD-L1 checkpoint inhibitors

  • European venture funding for the life science sector European venture funding for the life science sector

    is likely to accelerate interest - the sheer number of combination therapies and PD-1/PD-L1 inhibitors could result in a commoditisation of this area that could threaten returns for venture

  • Pharma deals continue to slide Pharma deals continue to slide

    1, 410 (upfront 80). WuXi Biologics and Gloria Pharma (CN). Arcus Biosciences (US). ... Licence to develop and commercialise. GLS-010, anti-PD-1 antibody in phase I for treatment of cancer.

  • Deal Watch January 2017 Deal Watch January 2017

    3, 050. Pieris Pharmaceuti-cals. Servier. Exclusive licence outside USA. PRS 332 PD-1-targeting bispecific checkpoint inhibitor and 4 other candidates. ... 775. BMS | Ono. Merck. Patent settlement. PD-1 antibody Keytruda - (pembrolizumab).

More from intelligence
Approximately 0 fully matching, plus 24 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

MAT offers an information exchange called Rapid Payer Response that allows healthcare stakeholders to secure immediate, global, expert insight and...

Latest intelligence

Lars Bruening
Shaping healthcare
Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes...
No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...

Quick links

Infographics

Multimedia